Background
Methods
Patients’ characteristics
Stable metastases | Unstable metastases | All patients | p-value | |||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | |||
Age (years) | Mean (SD) | 61.8 +/− 11.0 | 63.7 +/− 11.0 | 62.7 +/− 11.1 | 0.973 | |||
Gender | Male | 246 | 50 | 243 | 50 | 489 | 53 | 0.983 |
Female | 214 | 50 | 212 | 50 | 426 | 47 | ||
KPS | <80 | 195 | 46 | 227 | 54 | 422 | 46 | 0.023 |
> = 80 | 265 | 54 | 228 | 46 | 493 | 54 | ||
Primary site | ||||||||
NSCLC | 211 | 50 | 214 | 50 | 425 | 46 | 0.038 | |
Breast cancer | 83 | 47 | 92 | 53 | 175 | 20 | ||
Renal cancer | 72 | 45 | 87 | 55 | 159 | 17 | ||
Other | 94 | 60 | 62 | 40 | 156 | 17 | ||
Localization metastases | ||||||||
Thoracic | 275 | 49 | 288 | 51 | 563 | 62 | 0.275 | |
Lumbar | 185 | 53 | 167 | 47 | 352 | 38 | ||
Number metastases | ||||||||
Solitary | 243 | 58 | 174 | 42 | 417 | 46 | <0.001 | |
Multiple | 217 | 44 | 281 | 56 | 498 | 54 | ||
Other distant metastases | ||||||||
Liver | 102 | 55 | 84 | 45 | 186 | 20 | 0.163 | |
Brain | 71 | 56 | 56 | 44 | 127 | 14 | 0.176 | |
Lung | 111 | 58 | 81 | 42 | 192 | 21 | 0.019 | |
Skin | 26 | 72 | 10 | 28 | 36 | 4 | 0.007 | |
Bisphosphonates | 327 | 51 | 320 | 49 | 647 | 71 | 0.801 | |
Chemotherapy | 266 | 53 | 236 | 47 | 502 | 55 | 0.065 | |
Orthopedic corset | 140 | 32 | 302 | 68 | 442 | 48 | <0.001 | |
Radiotherapy schedule | ||||||||
10 × 3 Gy | 349 | 53 | 314 | 47 | 663 | 72 | 0.092 | |
14 × 2.5 Gy | 36 | 40 | 53 | 60 | 89 | 10 | ||
20 × 2 Gy | 68 | 45 | 82 | 55 | 150 | 16 | ||
Other | 7 | 54 | 6 | 46 | 13 | 1 |
Radiotherapy
Statistical analysis
Results
Stable metastases | Unstable metastases | p-value | |
---|---|---|---|
Overall survival | % | % | 0.851 |
6 months | 81 | 78 | |
1 year | 62 | 57 | |
2 years | 42 | 38 | |
5 years | 25 | 22 | |
Bone survival | % | % | 0.755 |
6 months | 57 | 59 | |
1 year | 38 | 39 | |
2 years | 22 | 19 | |
5 years | 8 | 8 |
Stable metastases | Unstable metastases | |||||
---|---|---|---|---|---|---|
Factor | Hazard Ratio | 95 % CI | p-value | Hazard Ratio | 95 % CI | p-value |
Age | 1.01 | 0.99–1.02 | 0.09 | 1.01 | 1.00–1.02 | 0.025 |
Gender | ||||||
Female | Reference | |||||
Male | 1.27 | 1.01–1.60 |
0.04
| 1.07 | 0.83–1.38 | 0.59 |
KPS | ||||||
> =80 % | Reference | |||||
< 80 % | 1.27 | 1.04–1.55 |
0.02
| 1.11 | 0.91–1.35 | 0.30 |
Primary site | ||||||
Breast cancer | Reference | |||||
NSCLC | 2.77 | 1.99–3.86 |
<0.0001
| 2.00 | 1.43–2.80 |
<0.0001
|
Renal cancer | 0.84 | 0.53–1.33 | 0.47 | 0.85 | 0.54–1.33 | 0.47 |
Localization of metastases | ||||||
Thoracic | Reference | |||||
Lumbar | 1.07 | 0.87–1.31 | 0.53 | 0.90 | 0.73–1.11 | 0.31 |
Number of metastases | ||||||
1 | Reference | |||||
> 1 | 1.16 | 0.95–1.41 | 0.13 | 1.35 | 1.11–1.65 |
0.003
|
Other distant metastases | ||||||
Liver yes | Reference | |||||
no | 0.72 | 0.56–0.92 |
0.008
| 0.71 | 0.54–0.92 |
0.003
|
Brain yes | Reference | |||||
no | 0.84 | 0.63–1.11 | 0.22 | 0.85 | 0.63–1.16 | 0.32 |
Lung yes | Reference | |||||
no | 1.27 | 0.99–1.62 | 0.06 | 1.05 | 0.79–1.40 | 0.73 |
Skin yes | Reference | |||||
no | 1.09 | 0.69–1.72 | 0.71 | 0.91 | 0.44–1.85 | 0.79 |
Bisphosphonates | ||||||
yes | Reference | |||||
no | 1.19 | 0.91–1.56 | 0.21 | 1.07 | 0.79–1.44 | 0.66 |
Chemotherapy | ||||||
yes | Reference | |||||
no | 0.84 | 0.68–1.02 | 0.08 | 0.97 | 0.79–1.19 | 0.79 |
Orthopedic corset | ||||||
yes | Reference | |||||
no | 0.84 | 0.67–1.06 | 0.14 | 0.77 | 0.62–0.96 |
0.02
|
Radiotherapy schedule | ||||||
> 30 Gy | Reference | |||||
< =30 Gy | 1.27 | 0.99–1.63 | 0.06 | 1.08 | 0.86–1.35 | 0.53 |